Group One Trading’s Actinium Pharmaceuticals ATNM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.29K | Sell |
2,300
-1,500
| -39% | -$1.78K | ﹤0.01% | 7013 |
|
|
2025
Q4 | $5.17K | Sell |
3,800
-10,800
| -74% | -$15.8K | ﹤0.01% | 7167 |
|
|
2025
Q3 | $23.4K | Sell |
14,600
-11,300
| -44% | -$18.4K | ﹤0.01% | 6583 |
|
|
2025
Q2 | $36.3K | Buy |
25,900
+900
| +4% | +$1.35K | ﹤0.01% | 5827 |
|
|
2025
Q1 | $40.3K | Buy |
25,000
+23,200
| +1,289% | +$29.4K | ﹤0.01% | 5323 |
|
|
2024
Q4 | $2.27K | Sell |
1,800
-7,900
| -81% | -$12.3K | ﹤0.01% | 6701 |
|
|
2024
Q3 | $18.2K | Buy |
9,700
+2,200
| +29% | +$8.69K | ﹤0.01% | 5279 |
|
|
2024
Q2 | $55.5K | Buy |
7,500
+2,700
| +56% | +$22.2K | ﹤0.01% | 4450 |
|
|
2024
Q1 | $37.6K | Sell |
4,800
-1,600
| -25% | -$10.3K | ﹤0.01% | 4949 |
|
|
2023
Q4 | $32.5K | Sell |
6,400
-41,900
| -87% | -$216K | ﹤0.01% | 5378 |
|
|
2023
Q3 | $286K | Buy |
48,300
+12,500
| +35% | +$83.2K | ﹤0.01% | 3476 |
|
|
2023
Q2 | $266K | Sell |
35,800
-7,500
| -17% | -$63.8K | ﹤0.01% | 3647 |
|
|
2023
Q1 | $409K | Sell |
43,300
-58,900
| -58% | -$622K | ﹤0.01% | 2961 |
|
|
2022
Q4 | $1.09M | Buy |
102,200
+9,300
| +10% | +$94.4K | ﹤0.01% | 2339 |
|
|
2022
Q3 | $686K | Buy |
92,900
+800
| +0.9% | +$4.97K | ﹤0.01% | 2921 |
|
|
2022
Q2 | $443K | Sell |
92,100
-51,000
| -36% | -$290K | ﹤0.01% | 3549 |
|
|
2022
Q1 | $731K | Buy |
143,100
+68,400
| +92% | +$360K | ﹤0.01% | 3413 |
|
|
2021
Q4 | $449K | Buy |
74,700
+22,500
| +43% | +$169K | ﹤0.01% | 4254 |
|
|
2021
Q3 | $462K | Sell |
52,200
-15,300
| -23% | -$106K | ﹤0.01% | 4284 |
|
|
2021
Q2 | $534K | Buy |
67,500
+6,300
| +10% | +$49.4K | ﹤0.01% | 4158 |
|
|
2021
Q1 | $466K | Buy |
61,200
+34,600
| +130% | +$294K | ﹤0.01% | 4119 |
|
|
2020
Q4 | $207K | Sell |
26,600
-99,700
| -79% | -$1.08M | ﹤0.01% | 4033 |
|
|
2020
Q3 | $1.22M | Buy |
+126,300
| New | +$1.39M | ﹤0.01% | 2015 |
|
|
2016
Q3 | – | Sell |
-1,233
| Closed | -$65K | – | 4527 |
|
|
2016
Q2 | $65K | Hold |
1,233
| – | – | ﹤0.01% | 3141 |
|
|
2016
Q1 | $74K | Buy |
1,233
+1,006
| +443% | +$63.5K | ﹤0.01% | 3018 |
|
|
2015
Q4 | $22K | Buy |
227
+114
| +101% | +$7.58K | ﹤0.01% | 3864 |
|
|
2015
Q3 | $6K | Sell |
113
-4
| -3% | -$267 | ﹤0.01% | 4445 |
|
|
2015
Q2 | $9K | Buy |
+117
| New | +$9.99K | ﹤0.01% | 4320 |
|
|
2015
Q1 | – | Sell |
-13
| Closed | -$2K | – | 4748 |
|
|
2014
Q4 | $2K | Buy |
+13
| New | +$2.47K | ﹤0.01% | 4675 |
|
Other funds holding ATNM
VCM
GS
VFT
Group One Trading's ATNM Position: Q4 2025 in Review
Group One Trading sold out of Actinium Pharmaceuticals (ATNM) in Q4 2025, closing a stake of 547 shares — an estimated $798 sold.
Group One Trading first reported a position in ATNM in Q4 2014 and held it in 25 quarters. The position peaked at $533K in Q3 2022. 60 funds tracked by Wall St. Rank hold ATNM as of Q4 2025.
- Group One Trading reported no remaining Actinium Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Group One Trading sold 547 Actinium Pharmaceuticals shares in Q4 2025, an estimated $798.
- Group One Trading first reported a position in Actinium Pharmaceuticals in Q4 2014 and held it in 25 quarters.
- Group One Trading's Actinium Pharmaceuticals position peaked at $533K in Q3 2022.
- 60 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2025.
Based on Group One Trading's 13F filing for Q4 2025, filed 12 Feb 2026.